Taken together, the results presented in this study strongly suggest that children with neuroblastoma tumors expressing high levels of BCL-2 and the BIM/BCL-2 complex might benefit from combined treatment with ABT199 and compounds that inhibit MCL-1. Here, BCL2 is linked to neuroblastoma.